Wall Street brokerages forecast that Immune Design Corp. (NASDAQ:IMDZ) will post earnings of ($0.68) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Immune Design Corp.’s earnings, with estimates ranging from ($0.74) to ($0.64). Immune Design Corp. posted earnings per share of ($0.60) in the same quarter last year, which would suggest a negative year over year growth rate of 13.3%. The firm is scheduled to issue its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Immune Design Corp. will report full-year earnings of ($2.34) per share for the current fiscal year, with EPS estimates ranging from ($2.54) to ($2.17). For the next year, analysts anticipate that the business will post earnings of ($2.03) per share, with EPS estimates ranging from ($2.43) to ($1.44). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that that provide coverage for Immune Design Corp..

Immune Design Corp. (NASDAQ:IMDZ) last released its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $1.50 million.

Several research firms have recently issued reports on IMDZ. ValuEngine raised Immune Design Corp. from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Royal Bank Of Canada began coverage on Immune Design Corp. in a research report on Thursday. They set an “outperform” rating and a $20.00 price objective for the company. Cowen and Company reaffirmed a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Immune Design Corp. in a research report on Wednesday, June 28th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Immune Design Corp. presently has an average rating of “Buy” and an average price target of $16.33.

In related news, Director Lewis W. Coleman acquired 8,000 shares of Immune Design Corp. stock in a transaction on Friday, July 7th. The stock was purchased at an average cost of $9.27 per share, with a total value of $74,160.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $370,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Wayne Gombotz sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $11.43, for a total value of $114,300.00. Following the sale, the insider now directly owns 33,054 shares of the company’s stock, valued at $377,807.22. The disclosure for this sale can be found here. Insiders bought a total of 30,000 shares of company stock valued at $272,760 over the last three months. Company insiders own 42.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Immune Design Corp. by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 8,418 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in Immune Design Corp. during the 2nd quarter valued at approximately $117,000. Alliancebernstein L.P. purchased a new stake in Immune Design Corp. during the 2nd quarter valued at approximately $118,000. Virtu KCG Holdings LLC purchased a new stake in Immune Design Corp. during the 2nd quarter valued at approximately $153,000. Finally, Trexquant Investment LP purchased a new stake in Immune Design Corp. during the 1st quarter valued at approximately $183,000. 51.46% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Immune Design Corp. (IMDZ) Expected to Announce Earnings of -$0.68 Per Share” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/09/18/immune-design-corp-imdz-expected-to-announce-earnings-of-0-68-per-share.html.

Immune Design Corp. (NASDAQ IMDZ) traded up 8.02% during midday trading on Friday, reaching $10.10. The company’s stock had a trading volume of 150,658 shares. Immune Design Corp. has a 1-year low of $4.50 and a 1-year high of $13.05. The firm’s market capitalization is $258.75 million. The stock’s 50-day moving average price is $9.69 and its 200 day moving average price is $7.90.

Immune Design Corp. Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design Corp. (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.